Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top

Current Oncology Reports

Issue 11/2016

Content (5 Articles)

Geriatric Oncology (AR MacKenzie, Section Editor)

Incorporating Geriatric Medicine Providers into the Care of the Older Adult with Cancer

Allison Magnuson, Beverly Canin, G. J. van Londen, Beatrice Edwards, Pamela Bakalarski, Ira Parker

Geriatric Oncology (AR MacKenzie, Section Editor)

Age-related Disparity: Breast Cancer in the Elderly

Rahul Gosain, YaoYao Pollock, Dharamvir Jain

Sarcomas (SR Patel, Section Editor)

Uterine Adenosarcoma: a Review

Michael J. Nathenson, Vinod Ravi, Nicole Fleming, Wei-Lien Wang, Anthony Conley

Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)

The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma

Julio Lambea, Urbano Anido, Olatz Etxániz, Luis Flores, Álvaro Montesa, Juan Manuel Sepúlveda, Emilio Esteban

Melanoma (RJ Sullivan, Section Editor)

Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era

Kevin Wood, Jason J. Luke

Oct 16
Issue: 10/2016
Dec 16
Issue: 12/2016

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits